Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV® (levoketoconazole) for Endogenous Cushing's Syndrome

Author's Avatar
May 11, 2020
Article's Main Image

Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020